Related Experiment Video
Updated: Nov 22, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Association of Level and Increase in D-Dimer With All-Cause Death and Poor Functional Outcome After Ischemic Stroke
Huiqing Hou1,2,3,4, Xianglong Xiang1,2,3, Yuesong Pan1,2,3
1Department of Neurology Beijing Tiantan Hospital, Capital Medical University Beijing China.
Insights
High D-dimer levels and increases between baseline and 90 days are linked to worse outcomes in stroke patients. This study highlights D-dimer as a key biomarker for predicting mortality and functional decline after ischemic stroke.
Area of Science:
- Neurology
- Hematology
- Biomarkers
Background:
- D-dimer is a recognized coagulation biomarker associated with adverse outcomes in stroke.
- Understanding its role in predicting long-term prognosis is crucial for patient management.
Purpose of the Study:
- To investigate the association between D-dimer levels and their changes over time with all-cause mortality and poor functional outcomes.
- To analyze D-dimer levels at baseline and 90 days post-event in patients with ischemic stroke or transient ischemic attack.
Main Methods:
- Data from 10,518 patients within 7 days and 6,268 at 90 days from the Third China National Stroke Registry (CNSRIII) study were analyzed.
- Multivariable Cox and logistic regression models assessed the association of D-dimer levels with 1-year all-cause death and poor functional outcomes (modified Rankin Scale ≥3).
Main Results:
- Higher baseline D-dimer levels were significantly associated with increased risk of all-cause death (aHR, 1.77) and poor functional outcome (aOR, 1.49) at 1 year.
- Elevated D-dimer levels at 90 days also independently predicted poor outcomes.
- An increase in D-dimer from baseline to 90 days was linked to higher mortality (aHR, 1.99) but not functional outcome.
Conclusions:
- Elevated D-dimer levels at baseline and 90 days are significant predictors of poor outcomes in ischemic stroke and transient ischemic attack patients.
- The increase in D-dimer levels between baseline and 90 days is associated with increased mortality risk.
- D-dimer serves as a valuable prognostic biomarker in the management of stroke patients.
Abstract:
Background D-dimer is involved in poor outcomes of stroke as a coagulation biomarker. We aimed to investigate the associations of the level and increase in D-dimer between baseline and 90 days with all-cause death or poor functional outcome in patients after ischemic stroke or transient ischemic attack. Methods and Results We collected data from the CNSRIII (Third China National Stroke Registry) study. The present substudy included 10 518 patients within 7 days (baseline) of ischemic stroke or transient ischemic attack and 6268 patients at 90 days. Poor functional outcome at 1 year was assessed on the basis of the modified Rankin Scale (≥3). Multivariable Cox regression or logistic regression was used to assess the association of D-dimer levels with all-cause death or poor functional outcome. D-dimer levels at 90 days were lower than those at baseline (1.4 µg/mL versus 1.7 µg/mL; P<0.001). Higher baseline D-dimer level was associated with all-cause death (adjusted hazard ratio [HR], 1.77; 95% CI, 1.25-2.52; P=0.001) and poor functional outcome (adjusted odds ratio [OR], 1.49; 95% CI, 1.23-1.80; P<0.001) during 1-year follow-up. Higher D-dimer level at 90 days was also associated with poor outcomes independently. Furthermore, an increase in D-dimer levels between baseline and 90 days was associated with all-cause death (since 90 days to 1 year after index event) (adjusted HR, 1.99; 95% CI, 1.12-3.53; P=0.019) but not with poor functional outcome (adjusted OR, 1.08; 95% CI, 0.82-1.41). Conclusions Our study shows that high level and an increase in D-dimer between baseline and 90 days are associated with poor outcomes in patients after ischemic stroke or transient ischemic attack.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

